Thrombopoietin messenger RNA (THPO mRNA)

Thrombopoietin (THPO) messenger RNA is the genetic template for the synthesis of thrombopoietin, the primary cytokine responsible for regulating megakaryopoiesis and platelet production (UniProt Consortium, 2023). It is primarily synthesized in the liver and kidneys, and its translation is tightly controlled by regulatory elements in the 5' untranslated region (UTR) to maintain homeostatic platelet levels (Ghilardi & Skoda, 1999). Mutations within the THPO mRNA sequence, particularly those affecting the upstream open reading frames (uORFs) in the 5' UTR, can lead to constitutive over-translation and hereditary thrombocytosis (Kuter, 2013). In modern pharmacology, THPO mRNA is utilized as a therapeutic modality through mRNA replacement technology, where synthetic mRNA is delivered to the liver to stimulate the production of endogenous THPO protein (Moderna, Inc., 2024). This approach is specifically investigated for treating thrombocytopenia in patients with chronic liver disease or those undergoing intensive chemotherapy. By providing the mRNA blueprint directly to cells, clinicians aim to restore physiological platelet counts while avoiding the immunogenicity issues associated with older recombinant protein versions. However, careful monitoring of platelet levels is required to mitigate the risk of thrombotic complications or bone marrow fibrosis associated with chronic overstimulation of the THPO pathway.

Other names

TPO mRNAMegakaryocyte growth and development factor mRNAMGDF mRNAMyeloproliferative leukemia virus oncogene ligand mRNATHPO transcript

mRNA replacement therapy to induce endogenous production of functional thrombopoietin protein